✦ LIBER ✦

Assessing the Optimal Level of Platelet Inhibition with GPIIb/IIIa Inhibitors in Patients Undergoing Coronary Intervention. Rationale and Design of the GOLD Study

✍ Scribed by Steven R. Steinhubl

Book ID: 110375900
Publisher: Springer US
Year: 2000
Tongue: English
Weight: 128 KB
Volume: 9
Category: Article
ISSN: 0929-5305
DOI: 10.1023/a:1018754309025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness of the transradial approac

Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes

✍ Marco De Carlo; Gabriele Borelli; Roberto Gistri; Nicola Ciabatti; Alessandra Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Stenting and glycoprotein IIb/IIIa inhib

Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)

✍ Gilles Montalescot; Frans Van de Werf; Dietrich C. Gulba; Álvaro Avezum; David B 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 2 views

## Abstract Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patie

Development and Validation of a Risk Sco

Development and Validation of a Risk Scoring Model to Predict Net Adverse Cardiovascular Outcomes after Primary Percutaneous Coronary Intervention in Patients Pretreated with 600 mg Clopidogrel: Rationale and Design of the RISK-PCI Study

✍ IGOR MRDOVIC; LIDIJA SAVIC; JOVAN PERUNICIC; MILIKA ASANIN; RATKO LASICA; JELENA 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Scientific rationale and study design of

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C

✍ J. McHutchison; M. Sulkowski 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB